{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T05:31:03Z","timestamp":1772947863436,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":218,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007764","name":"Lanzhou City Science and Technology Bureau","doi-asserted-by":"publisher","award":["2023-ZD-135"],"award-info":[{"award-number":["2023-ZD-135"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100536","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:25:47Z","timestamp":1755825947000},"page":"100536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rapid development of Philadelphia chromosome-negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy"],"prefix":"10.1016","volume":"24","author":[{"given":"Huan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lrr.2025.100536_bib0001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2025.100536_bib0002","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment","author":"Issa","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.lrr.2025.100536_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.cancergen.2019.07.008","article-title":"Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors","volume":"238","author":"Ni","year":"2019","journal-title":"Cancer Genet."},{"issue":"6","key":"10.1016\/j.lrr.2025.100536_bib0004","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s12185-020-03074-7","article-title":"Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy","volume":"113","author":"Nakamura","year":"2021","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.lrr.2025.100536_bib0005","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","article-title":"Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"108","author":"Kovitz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100536_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2017.04.066","article-title":"Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia","volume":"216-217","author":"Wasilewska","year":"2017","journal-title":"Cancer Genet."},{"issue":"7","key":"10.1016\/j.lrr.2025.100536_bib0007","first-page":"547","article-title":"Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy","volume":"40","author":"Yuan","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.lrr.2025.100536_bib0008","first-page":"110","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells","author":"Deininger","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.lrr.2025.100536_bib0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2169\/internalmedicine.50.4481","article-title":"Myelodysplastic syndrome with ph negative monosomy 7 chromosome following transient bone marrow dysplasia during Imatinib treatment for chronic myeloid leukemia","volume":"50","author":"Karimata","year":"2011","journal-title":"Intern. Med."},{"issue":"6","key":"10.1016\/j.lrr.2025.100536_bib0010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892500038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892500038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:52:48Z","timestamp":1772898768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221304892500038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":10,"alternative-id":["S221304892500038X"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100536","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid development of Philadelphia chromosome-negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100536"}}